Publications by authors named "C Ruiz Hierro"
Background: Bimiralisib is a pan-PI3K/mTOR inhibitor demonstrating antitumor efficacy in preclinical models. The objectives of this study were to identify a maximum tolerated dose (MTD), pharmacokinetics (PK), a dosing schedule, and adverse events (AEs) in patients with advanced solid tumors.
Patients And Methods: Patients received oral bimiralisib to determine the MTD of one continuous (once daily) and two intermittent schedules (A: Days 1, 2 weekly; B: Days 1, 4 weekly) until progression or unacceptable AEs occurred.
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry.
Clin Transl Oncol
July 2024
Article Synopsis
- The study investigates the effectiveness and tolerability of different chemotherapy regimens (FOLFOX, CAPOX, CP, and FP) for treating HER2-negative advanced esophagogastric cancer, using data from the AGAMENON-SEOM Spanish registry between 2008 and 2021.
- Results indicate that FOLFOX significantly improves progression-free survival (PFS) compared to the CP regimen, although treatment durations were similar among all groups.
- Adverse effects varied by regimen, with higher rates of fatigue and neuropathy seen in FOLFOX, while CP showed notable incidences of hand-foot syndrome and thromboembolic events.
Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10-20% of gastric cancers. The implementation of targeted therapy against HER2 as part of the standard of care treatment in metastatic disease has improved the prognosis of this subset of patients.
View Article and Find Full Text PDFIntroduction: Cancer patients often suffer from malnutrition and early detection and raising awareness of nutritional issues is crucial in this population.
Methods: The Spanish Oncology Society (SEOM) conducted the Quasar_SEOM study to investigate the current impact of the Anorexia-Cachexia Syndrome (ACS). The study employed questionnaires and the Delphi method to gather input from both cancer patients and oncologists on key issues related to early detection and treatment of ACS.
Article Synopsis
- Thoracoscopic repair of esophageal atresia (EA) and tracheoesophageal fistula (TEF) is gaining popularity, but there's ongoing debate about its use in patients with major congenital heart disease (CHD) or low birth weight (LBW).
- A retrospective analysis of 25 patients showed that 36% had major CHD, and there were no significant differences in surgical outcomes, including complications and operative time, between patients with and without these risk factors.
- The study concludes that thoracoscopic repair is feasible for patients with CHD or LBW, but each case should be evaluated individually due to the technical complexity of the procedure.